Together with our recent findings [6], which showed that CDK5 inhibition causes reduced HCC proliferation and clonogenic survival, this demonstrates the importance of CDK5 as an ideal and pharmacologically accessible therapeutic target with multiple modes of action in HCC. This evidence concerns the gene CDK5 and hepatocellular carcinoma.